via pharmalot.com
Insider hears:
Multaq sales will focus on existing specialist Rxer base,
Plavix promotion to end Dec 2011.
Puerto Rico restructuring.
Onology and Solid tumor resize due to patent losses and delays in launches,
Hematology integrating with Genzyme..
Diabetes will streamline field leadership. There will be voluntary severance packages offered by end of day to eligible employees.
No comments:
Post a Comment